The role of positron emission tomography with 18F-fluoro-2-deoxy-D-glucose in respiratory oncology

European Respiratory Journal

Volumn 17, Issue 4, 2001, Pages 802-820

  Vansteenkiste, J F ^a   Stroobants, S G ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

18F fluoro 2 deoxy D glucose; Decision trees; Emission computed tomography; Lung neoplasms; Non small cell lung carcinoma; Predictive value of tests

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG RESEARCH; EUROPE; HUMAN; IMAGING; LUNG CANCER; LUNG NODULE; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MOLECULAR BIOLOGY; MULTICENTER STUDY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REIMBURSEMENT; TREATMENT OUTCOME; TREATMENT PLANNING; VALIDATION PROCESS;

CARCINOMA, NON-SMALL-CELL LUNG; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0035021450     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.01.17408020     Document Type: Article

References (178)

1. Evaluation of the effect of thrombolytic treatment on infarct size and left ventricular function by enzymatic, scintigraphic and angiographic methods
2. A new quantitative method for the analysis of cardiac perfusion tomography (SPECT). Validation in patients treated with thrombolytic therapy
3. The metabolism of the carcinoma cell
4. Glucose utilization in vivo by human pulmonary neoplasms
5. The interaction among glucose transport, hexokinase, and glucose-6-phosphatase with respect to 3H-2-deoxy-glucose retention in murine tumor models
6. Over-expression of facilitative glucose transporter genes in human cancer
7. Labeled 2-deoxy-D-glucose analogs: 18F-labeled 2-deoxy-2-fluoro-D-glucose, 2-deoxy-2-fluoro-D-mannose and 14C-2-deoxy-2-fluoro-D-glucose
8. Physicochemical properties and isoenzyme composition of hexokinase from normal and malignant human tissues
9. The mechanism of accumulation of tumour-localising radiopharmaceuticals
10. 18F-2-deoxy-2-fluoro-D-glucose uptake into human tumor xenografts: Feasibility studies for cancer imaging with positron emission tomography
11. Metabolic and hemodynamic evaluation of brain metastases from small cell lung cancer with positron emission tomography
12. Differential uptake of TI-201 by small cell lung cancer in a patient with pneumoconiosis-related pulmonary nodules
13. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations
14. Different perceptual tasks performed with the same visual stimulus attribute activate different regions of the human brain: A PET study
15. Noninvasive determination of local cerebral metabolic rate of glucose in man
16. SUV: Standard uptake or silly useless value?
17. Simultaneous emission and transmission measurements for attenuation correction in whole-body PET
18. Validation of postinjection transmission measurements for attenuation correction in neurological FDG-PET studies
19. FDG imaging of lung nodules: A phantom study comparing SPECT, camera-based PET, and dedicated PET
20. Feasibility of fluorodeoxyglucose dual-head gamma camera coincidence imaging in the evaluation of lung cancer: Comparison with FDG-PET
21. Imaging of lung cancer with fluorine-18 fluorodeoxyglucose: Comparison of a dual-head gamma camera in coincidence mode with a full-ring positron emission tomography system
22. Can dual-headed 18F-FDG SPET imaging reliably supersede PET in clinical oncology? A comparative study in lung and gastrointestinal tract cancer
23. Oncologic diagnosis with 2-[fluorine-18]fluoro-2-deoxy-D-glucose imaging: Dual-head coincidence gamma camera versus positron emission tomographic scanner
24. Managing solitary pulmonary nodules. The choice of strategy is a "close call"
25. Does 2-year stability imply that pulmonary nodules are benign?
26. The role of bronchoscopy in lung cancer
27. CT-guided fine-needle aspiration cytology of solitary pulmonary nodules: A prospective, randomized study of immediate cytologic evaluation
28. Percutaneous transthoracic needle aspiration biopsy: A comprehensive review of its current role in the diagnosis and treatment of lung tumors
29. Pitfalls of transthoracic needle aspiration biopsy
30. Fluorodeoxyglucose-positron emission tomography in the detection and staging of lung cancer
31. Prospective investigation of positron emission tomography in lung nodules
32. Detection of primary and recurrent lung cancer by means of F-18 fluoro-deoxyglucose positron emission tomography (FDG-PET)
33. Probability of malignancy in solitary pulmonary nodules using fluorine-18-FDG and PET
34. The use of positron emission tomography (PET) in the differential diagnosis of indeterminate solitary pulmonary lesions
35. Focal pulmonary abnormalities: Evaluation with F-18 fluorodeoxy-glucose PET scanning
36. Evaluation of the solitary pulmonary nodule by positron emission tomography imaging
37. Satellite PET and lung cancer: A prospective study in surgical patients
38. Diagnostic efficacy of PET-FDG imaging in solitary pulmonary nodules. Potential role in evaluation and management
39. Differential diagnosis of lung tumor with positron emission tomography: A prospective study
40. Solitary pulmonary nodules: Detection of malignancy with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose
41. Dynamic positron emission tomography with F-18 fluorodeoxyglucose imaging in differentiation of benign from malignant lung/mediastinal lesions
42. Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities
43. Positron emission tomography of lung tumors and mediastinal lymph nodes using [18F]fluorodeoxyglucose. The Members of the PET-Lung Tumor Study Group
44. Evaluation of primary pulmonary carcinoid tumors using FDG-PET
45. Comparison of fluorine-18-FDG-PET and thallium-201 SPECT in evaluation of lung cancer
46. Fluorine-18-FDG-PET imaging is negative in bronchioloalveolar lung carcinoma
47. Localized form of bronchioloalveolar carcinoma: FDG-PET findings
48. Fluorine-18-fluorodeoxyglucose uptake in pneumonia
49. Fluorine-18 deoxyglucose uptake in sarcoidosis measured with positron emission tomography
50. F-18 fluorodeoxyglucose chest uptake in lung inflammation and infection
51. Analytical decision model for the cost-effective management of solitary pulmonary nodules
52. Cost-effectiveness of FDG-PET for staging non-small cell lung cancer: A decision analysis
53. Decision-tree sensitivity analysis for cost-effectiveness of chest 2-fluoro-2-D-[(18)F]fluoro-deoxyglucose positron emission tomography in patients with pulmonary nodules (non-small cell lung carcinoma) in Japan
54. Lung nodule enhancement at CT: Prospective findings
55. Differentiation of malignant from benign solitary pulmonary lesions using chest radiography, spiral CT and HRCT
56. A twenty-five-year follow-up of ninety-three resected typical carcinoid tumors of the lung
57. Bronchioloalveolar carcinoma: Focal area of ground-glass attenuation at thin-section CT as an early sign
58. Magnetic resonance (MR) imaging of the chest: State-of-the-art
59. Present status of induction treatment for N2 non-small cell lung cancer: A review
60. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non small cell lung cancer
61. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer
62. Randomized trial of neoadjuvant therapy for lung cancer: Interim analysis
63. Randomized trial of surgery versus radiotherapy in patients with stage IIIA non-small cell lung cancer after a response to induction-chemotherapy. Inter-group study 08941
64. Bronchogenic carcinoma: Analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling
65. Mediastinal nodes in bronchogenic carcinoma: Comparison between CT and mediastinoscopy
66. Comparative merits of conventional, computed tomographic, and magnetic resonance imaging in assessing mediastinal involvement in surgically confirmed lung carcinoma
67. Prospective evaluation of computed tomography and mediastinoscopy in mediastinal lymph node staging
68. CT and MR imaging in staging non-small cell bronchogenic carcinoma: Report of the Radiology Diagnostic Oncology Group
69. Value of computed tomography and mediastinoscopy in preoperative evaluation of mediastinal nodes in non-small cell lung cancer
70. Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer
71. Staging non-small cell lung cancer by whole-body positron emission tomographic imaging
72. Lymph node staging in non-small cell lung cancer with FDG-PET scan: A prospective study on 690 lymph node stations from 68 patients
73. PET, CT, and MRI with Combidex for mediastinal staging in non-small cell lung carcinoma
74. FDG-PET scan in potentially operable non-small cell lung cancer: Do anatometabolic PET-CT fusion images improve the localisation of regional lymph node metastases?
75. Mediastinal lymph node staging with FDG-PET scan in patients with potentially operable non-small cell lung cancer: A prospective analysis of 50 cases
76. Staging of the mediastinum: Value of positron emission tomography imaging in non-small cell lung cancer
77. Accuracy and clinical impact of mediastinal lymph node staging with FDG-PET imaging in potentially resectable lung cancer
78. Non-small cell lung cancer: Nodal staging with FDG-PET versus CT with correlative lymph node mapping and sampling
79. Thoracic nodal staging with PET imaging with 18FDG in patients with bronchogenic carcinoma
80. Mediastinal staging of non-small-cell lung cancer with positron emission tomography
81. Mediastinal lymph node staging of non-small-cell lung cancer: A prospective comparison of computed tomography and positron emission tomography
82. Improvement of non-small-cell lung cancer staging by means of positron emission tomography
83. Staging of mediastinal non-small cell lung cancer with FDG-PET, CT, and fusion images: Preliminary prospective evaluation
84. F-18 fluorodeoxyglucose positron emission tomography in the non-invasive staging of non-small cell lung cancer
85. The usefulness of FDG positron emission tomography for the detection of mediastinal lymph node metastases in patients with non-small cell lung cancer: A comparative study with X-ray computed tomography
86. Metastases from non-small cell lung cancer: Mediastinal staging in the 1990s. Meta-analytic comparison of PET and CT
87. Surgical management of non-small cell lung cancer with ipsilateral mediastinal node metastasis (N2 disease)
88. Survival and prognostic factors in resected N2 non-small cell lung cancer: A study of 140 cases
89. Prognostic significance of computed tomography in resected N2 lung cancer
90. Mediastinal metastases in bronchogenic carcinoma: Influence of postoperative irradiation, cell type, and location
91. Significance of positive superior mediastinal nodes identified at mediastinoscopy in patients with resectable cancer of the lung
92. Five year survival in resected T3/N2 lung cancer
93. Induction therapy for NSCLC: A consensus report
94. The role of surgery in N2 lung cancer
95. The practice of cardiothoracic surgeons in the perioperative staging of non-small cell lung cancer
96. Patterns of disease failure after trimodality therapy of non-small cell lung carcinoma pathologic stage IIIA (N2)
97. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small cell lung carcinoma
98. Pretreatment evaluation of non-small cell lung cancer. The American Thoracic Society and The European Respiratory Society
99. Pretreatment minimal staging for non-small cell lung cancer: An updated consensus report
100. Incidence of local recurrence and second primary tumors in resected stage I lung cancer
101. Postsurgical stage I bronchogenic carcinoma: Morbid implications of recurrent disease
102. The first site of recurrence after complete resection in non-small cell carcinoma of the lung. Comparison between pNO disease and pN2 disease
103. Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small cell lung cancer without overt metastases
104. Distribution of distant metastases from newly diagnosed non-small cell lung cancer
105. Cancer statistics 1997
106. Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer
107. Sensitivity in detecting osseous lesions depends on anatomic localization: Planar bone scintigraphy versus 18F-PET
108. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma
109. Detection of bone metastases in breast cancer by 18FDG-PET: Differing metabolic activity in osteoblastic and osteolytic lesions
110. Isolated adrenal masses in non-small cell bronchogenic carcinoma
111. Preoperative CT evaluation of adrenal glands in non-small cell bronchogenic carcinoma
112. Non-small cell lung carcinoma adrenal metastases. Computed tomography and percutaneous needle biopsy in their diagnosis
113. Prospective evaluation of unilateral adrenal masses in patients with operable non-small cell lung cancer
114. Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography
115. Indeterminate adrenal mass in patients with cancer: Evaluation at PET with 2-[F-18]-fluoro-2-deoxy-D-glucose
116. Imaging of adrenal tumors using FDG PET: Comparison of benign and malignant lesions
117. Lung cancer staging and management: Comparison of contrast-enhanced and nonenhanced helical CT of the thorax
118. Detection of extrathoracic metastases by positron emission tomography in lung cancer
119. Staging non-small cell lung cancer with whole-body PET
120. Clinical evaluation of whole-body 18F-fluorodeoxyglucose positron emission tomography in the detection of liver metastases
121. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: Correlation with histopathologic and CT findings
122. Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose in recurrent colorectal cancer
123. Contribution of PET in the detection of liver metastases from pancreatic tumours
124. Computed tomography and positron emission tomography in the pre-operative staging of oesophageal carcinoma
125. Evaluation of benign vs malignant hepatic lesions with positron emission tomography
126. Brain metastases from non-central nervous system tumors: Evaluation with PET
127. Staging of non-small cell lung cancer by whole-body fluorine-18 deoxyglucose positron emission tomography
128. Whole-body 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer
129. Preliminary results of a prospective trial using three dimensional radiotherapy for lung cancer
130. Radiation pneumonitis as a function of mean lung dose: An analysis of pooled data of 540 patients
131. Physical and biological predictors of changes in whole-lung function following thoracic irradiation
132. Dose-volume histogram and 3-D treatment planning evaluation of patients with pneumonitis
133. Positron emission tomography in the pretreatment evaluation and follow-up of non-small cell lung cancer patients treated with radiotherapy: Preliminary findings
134. 18F-deoxy-glucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: High impact in patients with atelectasis
135. The impact of (18)F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer
136. The contribution of 18F-fluoro-2-deoxy-glucose positron emission tomographic imaging to radiotherapy planning in lung cancer
137. Multi-modality nuclear medicine imaging in three-dimensional radiation treatment planning for lung cancer: Challenges and prospects
138. A clinical evaluation of FDG-PET to assess the response in radiation therapy for bronchogenic carcinoma
139. Evaluation of the treatment response of lung cancer with positron emission tomography and L-[methyl-11C]methionine: A preliminary study
140. Thoracic radiotherapy does not prolong survival in patients with locally advanced, unresectable non-small cell lung cancer
141. Preoperative chemotherapy for stage IIIa (N2) lung cancer: The Sloan-Kettering experience with 136 patients
142. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: Mature results of Southwest Oncology Group phase II study 8805
143. Accelerated induction therapy and resection for poor prognosis stage III non-small cell lung cancer
144. Combined modality therapy for stage IIIA non-small cell carcinoma of the lung
145. Neo-adjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non-small-cell carcinoma of the lung: Report of a Cancer and Leukemia Group B phase II study
146. Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer
147. Pathologic complete response in advanced non-small-cell lung cancer following preoperative chemotherapy: Implications for the design of future non-small-cell lung cancer combined modality trials
148. Potential use of FDG-PET scan after induction chemotherapy in surgically staged IIIA-N2 non-small cell lung cancer: A prospective pilot study
149. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small cell lung cancer
150. Summary of phase II data of docetaxel (Taxotere), an active agent in the first- and second-line treatment of advanced non-small cell lung cancer
151. Activity of docetaxel in platinum-treated non-small cell lung cancer: Results of a phase II multicenter trial
152. Gemcitabine as second-line treatment for advanced non-small cell lung cancer: A phase II trial
153. A phase II trial testing gemcitabine as second-line chemotherapy for non-small cell lung cancer
154. Positron emission tomography for treatment evaluation and recurrence detection compared with CT in long-term follow-up cases of lung cancer
155. Detecting recurrent or residual lung cancer with FDG-PET
156. Persistent or recurrent bronchogenic carcinoma: Detection with PET and 2-[F-18]-2-deoxy-D-glucose
157. Decision logic for retreatment of asymptomatic lung cancer recurrence based on positron emission tomography findings
158. Value of FDG-PET in detecting residual or recurrent non-small cell lung cancer
159. Molecular abnormalities in lung cancer
160. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression
161. Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer
162. Angiogenesis and molecular biologic substaging in patients with stage I non-small cell lung cancer
163. Prognostic factors for survival in patients with inoperable lung cancer
164. Hormonal treatment in advanced non-small cell lung cancer: Fact or fiction?
165. Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography
166. Prognostic importance of the Standardized Uptake Value on FDG-PET-scan in non-small cell lung cancer: An analysis of 125 cases
167. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with non-small cell lung carcinoma
168. Prognostic value of thoracic FDG-PET imaging after treatment for non-small cell lung cancer
169. PET instrumentation: What are the limits?
170. PET radiopharmaceuticals: State-of-the-art and future prospects
171. Evaluation of 9-[(3-18F-fluoro-1-hydroxy-2-propoxy)methyl]guanine ([18F]-FHPG) in vitro and in vivo as a probe for PET imaging of gene incorporation and expression in tumors
172. Synthesis and preliminary evaluation of 9-(4-[18F]-fluoro-3-hydroxymethylbutyl) guanine ([18F]FHBG): A new potential imaging agent for viral infection and gene therapy using PET
173. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: Initial evaluation
174. Detection of DNA synthesis in intact organisms with positron-emitting (methyl-11C)thymidine
175. Carbon-11-thymidine and FDG to measure therapy response
176. Synthesis of 2′-fluoro-5-[11C]-methyl-1-beta-D-arabinofuranosyluracil ([11C]-FMAU): A potential nucleoside analog for in vivo study of cellular proliferation with PET
177. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography
178. Can positron emission tomography (PET) be used to detect subclinical response to cancer therapy?